WENDY BODWELL: Open Payments
NPI 1356957641 · ALBION, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$627 in 44 payments from 10 companies in 2025. Trend: 2023 $335 · 2024 $559 · 2025 $627
Food & beverage: $627
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 24 | $239 |
| Teva Pharmaceuticals USA, Inc. | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $70 |
| Neurocrine BioSciences, Inc. | 3 | $55 |
| Alkermes, Inc. | 2 | $43 |
| ABBVIE INC. | 2 | $37 |
| Lundbeck LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: COBENFY, CAPLYTA, UZEDY, INGREZZA, AUSTEDO XR, ABILIFY ASIMTUFII, ARISTADA, VRAYLAR.
Industry payments across IN — which companies pay providers there.
